Geron (NASDAQ:GERN) Announces Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Geron (NASDAQ:GERN) posted its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.01), Zacks reports. The company had revenue of $57.48 million during the quarter, compared to analysts’ expectations of $55.30 million. Geron had a negative return on equity of 23.31% and a negative net margin of 35.48%.

Here are the key takeaways from Geron’s conference call:

• RYTELO net revenue rose 17% year over year to $57.5 million in the second quarter, while first-half revenue increased approximately 24% year over year.
• RYTELO demand grew 5% sequentially, prescribing accounts increased 8% to approximately 1,575, and the company expects 2026 net product revenue of $220 million-$240 million to land at the mid-to-high end of guidance.
• Management cited encouraging real-world evidence in lower-risk MDS that was generally consistent with the Phase III IMerge trial, supporting RYTELO adoption—particularly in earlier lines of therapy and community treatment centers.
• Geron ended the quarter with $327 million in cash, equivalents, restricted cash, and marketable securities, while maintaining 2026 operating expense guidance of $230 million-$240 million and reporting a 4% first-half decrease in operating expenses.
• The company is evaluating a modification to the interim event threshold for the Phase III IMpactMF myelofibrosis trial after discussions with regulators; although timelines remain unchanged, the base case still calls for final overall-survival analysis in the second half of 2028.

Geron Price Performance

NASDAQ GERN traded down $0.06 during trading hours on Thursday, reaching $1.57. The company’s stock had a trading volume of 7,189,496 shares, compared to its average volume of 15,104,426. Geron has a 1-year low of $1.04 and a 1-year high of $2.01. The company has a debt-to-equity ratio of 0.52, a current ratio of 6.78 and a quick ratio of 4.96. The company’s 50-day moving average is $1.33 and its two-hundred day moving average is $1.46. The firm has a market capitalization of $1.01 billion, a price-to-earnings ratio of -14.32 and a beta of 0.61.

Geron News Summary

Here are the key news stories impacting Geron this week:

• Positive Sentiment: RYTELO sales beat expectations. Geron generated $57.5 million in second-quarter RYTELO (imetelstat) net product revenue, up 11% from the prior quarter and above the roughly $55.3 million analyst consensus. The performance indicates continued demand for the company’s commercial product. Geron Corporation Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Revenue growth and guidance were maintained. Management reiterated its 2026 RYTELO revenue outlook of $220 million to $240 million and total operating expense guidance of $230 million to $240 million. Geron ended the quarter with $327 million in cash, restricted cash and marketable securities, supporting near-term commercialization efforts. Geron Adds a Record 16% as Rytelo Drives Q2 Revenue Beat
• Neutral Sentiment: Options activity points to speculative bullish interest. Investors purchased 10,326 call options, approximately 15 times the average volume. This may provide short-term trading support, but it does not represent a change in Geron’s underlying business performance.
• Negative Sentiment: Geron missed on quarterly EPS. The company reported a loss of $0.02 per share versus the $0.01 consensus loss estimate, keeping profitability a concern despite the revenue beat. Geron Reports Q2 Loss and Beats Revenue Estimates
• Negative Sentiment: HC Wainwright cut its long-term EPS forecasts. Estimates were reduced for FY2027 through FY2030, including FY2028 EPS to $0.12 from $0.16 and FY2030 EPS to $0.55 from $0.59. The revisions suggest analysts now expect a slower path to profitability. Geron Analyst Estimates

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded shares of Geron from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, July 24th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Geron presently has a consensus rating of “Hold” and a consensus target price of $4.00.

Institutional Investors Weigh In On Geron

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd lifted its position in shares of Geron by 3,307.6% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 25,148 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 24,410 shares in the last quarter. Amundi acquired a new position in Geron in the fourth quarter valued at $38,000. Franklin Resources Inc. acquired a new stake in shares of Geron during the third quarter worth about $45,000. Cibc World Markets Corp purchased a new stake in Geron during the 4th quarter valued at approximately $48,000. Finally, Atom Investors LP lifted its stake in shares of Geron by 137.0% in the 4th quarter. Atom Investors LP now owns 37,341 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 21,588 shares during the period. Institutional investors and hedge funds own 73.71% of the company’s stock.

Geron Company Profile

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.